Genetics-Driven Novel Target Discovery
Integrative multi-omics pipeline for identifying and validating drug targets at Pfizer.
At Pfizer’s Internal Medicine Research Unit, I contributed to target discovery programs for cardiovascular and renal disease by bringing computational genetics expertise. The core approach integrated human genetic evidence (GWAS, exome-wide association studies, colocalization, and Mendelian randomization) with functional genomics layers including single-cell chromatin accessibility, eQTL and pQTL datasets, and deep learning-based functional predictions to nominate and prioritize novel targets with genetic support for efficacy and selectivity. Several targets identified through this pipeline advanced into the Pfizer portfolio.
Beyond individual target programs, I led the development of cloud-native genomics infrastructure enabling large-scale analyses across the organization: scalable GWAS and fine-mapping pipelines , standardized summary statistics harmonization, and integration of emerging multi-omics datasets.